MAPT and Alzheimer disease: This is even more true in the case of tau biomarkers: indeed, the A/T/N criteria not only require positivity to tau pathology to define clinical AD but also categorize individuals with positive tau and negative Aβ as belonging to the continuum of non-AD progressive neurodegenerative disorders (Table 2 in [1]).